Gastric ulcer: a double-blind comparison of 100 mg pirenzepine plus antacid versus 800 mg cimetidine plus antacid. 1986

J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine

Fifty-five patients with endoscopically confirmed gastric ulcers received either cimetidine (28 patients) or pirenzepine (27 patients) in a randomized double-blind manner. Fifty-seven per cent of the patients treated with cimetidine and 48% of those treated with pirenzepine presented with endoscopically healed ulcers after 4 weeks of treatment. By 8 weeks complete healing had occurred in 83% of the patients taking cimetidine and 76% of those taking pirenzepine. These differences were not statistically significant. Severity of pain on entering the study was correlated with slower healing of the ulcer. Side effects occurred in 5 of 27 patients in the pirenzepine group and 3 of 28 in the cimetidine group. They were mostly mild and did not differ from side effects observed in other studies.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010890 Pirenzepine An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients. Gastrotsepin,Gastrozepin,L-S 519,LS-519,Piren-Basan,Pirenzepin,Pirenzepin Von Ct,Pirenzepin-Ratiopharm,Pirenzepine Dihydrochloride,Pyrenzepine,Ulcoprotect,Ulgescum,Dihydrochloride, Pirenzepine,LS 519,LS519,Piren Basan,Pirenzepin Ratiopharm,Von Ct, Pirenzepin
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
October 1987, Hepato-gastroenterology,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
January 1982, Digestion,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
January 1988, Digestion,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
February 1978, Gastroenterology,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
July 1982, La Clinica terapeutica,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
June 1983, The New England journal of medicine,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
January 1986, Scandinavian journal of gastroenterology. Supplement,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
November 1988, Zeitschrift fur Gastroenterologie,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
July 1979, The Medical journal of Australia,
J J Gonvers, and S Realini, and A Bretholz, and M Voirol, and J Arnold, and R Birchler, and J B Ollyo, and J Guyot, and Y Capitaine
December 1981, The American journal of gastroenterology,
Copied contents to your clipboard!